Health Blueprint

Back to Longevity News

News summary

Everolimus-induced Regression of a Low-grade Oncocytic Renal Tumour in a Germline TSC1 Carrier: Expanding the Therapeutic and Phenotypic Spectrum of Tuberous Sclerosis Complex-Associated Neoplasia

Source: Frontiers - Health • Published: 27 Oct 2026, 00:00

Summarized by Masters of Longevity from Frontiers - Health.

A germline TSC1 carrier’s bilateral LOTs regressed on systemic everolimus treatment.

Everolimus-induced Regression of a Low-grade Oncocytic Renal Tumour in a Germline TSC1 Carrier: Expanding the Therapeutic and Phenotypic Spectrum of Tuberous Sclerosis Complex-Associated Neoplasia
Key Takeaways
  • Bilateral renal masses were 12 cm and 6 cm at presentation.
  • Biopsy showed a CK7+/CD117- eosinophilic tumour consistent with LOT.
  • Tumour regression was observed after six and 12 months of everolimus.
Read the full article at Frontiers - Health ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickMOTS-c: Where the Evidence EndsStudies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.